Download PDF

1. Company Snapshot

1.a. Company Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.


In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F.Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd.


The company was formerly known as Hoyle Pharmaceuticals, Inc.and changed its name to Blueprint Medicines Corporation in June 2011.Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on BPMC

The recent performance of Blueprint Medicines Corporation was driven by the proposed acquisition by Sanofi, a deal valued at up to $9.5 billion. This transaction includes the approval of AYVAKIT/AYVAKYT (avapritinib) for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline. The deal's potential to expand Sanofi's immunology portfolio and add a fast-growing product to its portfolio contributed to the positive sentiment. Additionally, the company's recent data presentations reinforcing the sustained clinical efficacy and well-tolerated safety profile of long-term AYVAKIT/AYVAKYT treatment at the 2025 EHA and EAACI Congresses further supported the positive drivers.

1.c. Company Highlights

2. Blueprint Medicines Delivers Strong Q1 2025 Results, Raises Guidance, and Advances Pipeline

Blueprint Medicines reported a standout Q1 2025 performance, with AYVAKIT revenue surging 61% year-over-year to $149.4 million, surpassing analyst estimates. The company raised its full-year revenue guidance to $700-$720 million, reflecting strong patient demand and a favorable free vs. paid goods mix. Notably, the company reported an EPS of $0.01, significantly outperforming the consensus estimate of -$0.42, underscoring operational efficiency and profitability improvements.

Publication Date: May -01

📋 Highlights
  • AYVAKIT Revenue Growth: AYVAKIT revenue grew 61% year-over-year, reaching $149.4 million in Q1 2025.
  • Raised Full-Year Guidance: The company raised its full-year revenue guidance to $700-$720 million, driven by strong patient demand.
  • Market Penetration: AYVAKIT captured 20% of diagnosed U.S. SM patients, supporting the $2 billion annual revenue goal by 2030.
  • Strong Cash Position: Blueprint Medicines reported a strong cash position of $900 million, ensuring financial stability and growth investments.
  • Therapeutic Expansion: The company plans to expand into GI and dermatology starting in 2026, targeting untapped patient populations.

Commercial Momentum Drives Growth

AYVAKIT continued to gain traction in systemic mastocytosis (SM), achieving 20% penetration of diagnosed U.S. patients and reinforcing the pathway to the $2 billion annual revenue target by 2030. Management highlighted that patient starts and persistence rates aligned with expectations, supported by an activated prescriber base and effective direct-to-patient initiatives. International growth, particularly in Germany, was robust, with ex-US revenue nearly doubling year-over-year despite Q1 flatness due to timing and FX factors. The free goods rate remained durable and below 10%, de-risking the outlook for future quarters.

Pipeline Progress Strengthens Future Growth Prospects

Blueprint Medicines advanced its pipeline with two proof-of-concept studies for BLU-808 in allergic rhinoconjunctivitis and chronic urticaria, and the pivotal Harbor study for elenestinib progressed as planned. Management emphasized the unique dosing strategy for BLU-808, exploring doses from 1-6 mg to optimize symptom resolution and maintenance, leveraging mast cell dynamics. The company also highlighted its disciplined approach to R&D spending, with a focus on high-priority programs like elenestinib and BLU-808.

Valuation Analysis

With a price-to-sales (P/S) ratio of 12.6, the stock reflects the market's confidence in the company's growth trajectory. The strong cash position of $900 million and disciplined capital allocation further support the durable financial profile. Management's strategic focus on out-licensing non-core programs, such as the recent $80 million deal with IDRx, underscores its ability to maintain financial sustainability while investing in high-growth opportunities. Analysts estimate 31.0% revenue growth for next year, positioning Blueprint Medicines as a compelling long-term growth story in the biopharmaceutical sector.

3. NewsRoom

Card image cap

Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction

Aug -27

Source: businesswire.com

Card image cap

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of First Community Corporation (NASDAQ: FCCO)

Jul -14

Source: globenewswire.com

Card image cap

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

Jun -20

Source: businesswire.com

Card image cap

HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC)

Jun -15

Source: globenewswire.com

Card image cap

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

Jun -12

Source: prnewswire.com

Card image cap

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

Jun -02

Source: youtube.com

Card image cap

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

Jun -02

Source: zacks.com

Card image cap

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

Jun -02

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (15.40%)

6. Segments

Precision Therapies

Expected Growth: 15.4%

Growing demand for targeted cancer treatments, increasing prevalence of cancer, and advancements in genetic research drive the growth of Precision Therapies from Blueprint Medicines Corporation.

7. Detailed Products

AYVAKIT

A kinase inhibitor for the treatment of systemic mastocytosis

GAVRETO

A RET inhibitor for the treatment of RET-altered thyroid cancers and RET fusion-positive non-small cell lung cancer

Praxis

A precision medicine platform for identifying and developing targeted therapies

Compass

A patient identification and access platform for rare genetic diseases

8. Blueprint Medicines Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Blueprint Medicines Corporation is medium, as there are some alternative treatments available for cancer and rare genetic diseases, but they are not yet widely adopted.

Bargaining Power Of Customers

The bargaining power of customers for Blueprint Medicines Corporation is low, as patients and healthcare providers have limited negotiating power due to the company's specialized products.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Blueprint Medicines Corporation is medium, as the company relies on a few key suppliers for raw materials and manufacturing services.

Threat Of New Entrants

The threat of new entrants for Blueprint Medicines Corporation is high, as the biotechnology industry is highly competitive and new companies are emerging with innovative technologies.

Intensity Of Rivalry

The intensity of rivalry for Blueprint Medicines Corporation is high, as the company operates in a highly competitive industry with many established players and new entrants.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 84.13%
Debt Cost 6.65%
Equity Weight 15.87%
Equity Cost 7.21%
WACC 6.74%
Leverage 530.11%

11. Quality Control: Blueprint Medicines Corporation passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Blueprint Medicines

A-Score: 5.2/10

Value: 6.0

Growth: 7.1

Quality: 5.2

Yield: 0.0

Momentum: 9.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
SpringWorks Therapeutics

A-Score: 5.1/10

Value: 6.2

Growth: 4.4

Quality: 5.0

Yield: 0.0

Momentum: 9.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Krystal Biotech

A-Score: 4.8/10

Value: 1.2

Growth: 9.7

Quality: 9.1

Yield: 0.0

Momentum: 5.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Sarepta Therapeutics

A-Score: 3.2/10

Value: 6.4

Growth: 7.9

Quality: 4.2

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Avidity Biosciences

A-Score: 3.2/10

Value: 6.2

Growth: 2.7

Quality: 5.1

Yield: 0.0

Momentum: 4.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Crinetics Pharmaceuticals

A-Score: 2.5/10

Value: 6.4

Growth: 1.1

Quality: 3.9

Yield: 0.0

Momentum: 1.0

Volatility: 2.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

129.46$

Current Price

129.46$

Potential

-0.00%

Expected Cash-Flows